The role of vascular cell adhesion molecule-1 in tumor immune evasion

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6003-6006

  Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; VASCULAR CELL ADHESION MOLECULE 1;

CANCER RESEARCH; CELLULAR IMMUNITY; ENDOTHELIUM CELL; EXTRAVASATION; INFLAMMATION; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR CELL; TUMOR IMMUNOLOGY;

CARCINOMA, RENAL CELL; CELL ADHESION; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNE SYSTEM; INTEGRINS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASMS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 34447120196     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1543     Document Type: Review

References (16)

1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
2. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
3. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
4. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
5. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241-51.
6. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
7. Lin KY, Lu D, Hung CF, et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007;67:1832-41.
8. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
9. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995;92:11671-5.
10. Petruzzelli L, Takami M, Humes HD. Structure and function of cell adhesion molecules. Am J Med 1999;106:467-76.
11. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007;14:377-86.
12. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
13. 4 integrins and the immune response. Immunol Rev 2002;186:118-24.
14. 4 integrins modifies integrin-dependent biological responses. Nature 1999;402:676-81.
15. 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol 2003;170:5912-8.
16. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.